Evidence map›Paper›PMID 42286727›Full record

ArticleJournal of experimental & clinical cancer research : CR2026

Inhibition of 5'-tiRNA

Xinliang Gu, Yu Zhang, Yang Li, Xun Li, Yuening Sun, Shuo Ma, Xinyue Qin, Yuejiao Huang, Xianjuan Shen, Ming Zheng and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xinliang Gu *Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Xisi Road, No.20, Nantong, Jiangsu, 226001, China.
Yu Zhang *Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Xisi Road, No.20, Nantong, Jiangsu, 226001, China.
Yang Li *Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Xisi Road, No.20, Nantong, Jiangsu, 226001, China.
Xun LiDepartment of Laboratory Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Xisi Road, No.20, Nantong, Jiangsu, 226001, China.
Yuening SunDepartment of Pharmacy, Affiliated Hospital of Nantong University, Pharmacy School of Nantong University, Xisi Road, No.20, Nantong, Jiangsu, 226001, China.
Shuo MaCenter of Clinical Laboratory Medicine, Zhongda Hospital, Medical School of Southeast University, Nanjing, 210009, China.
Xinyue QinDepartment of Laboratory Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Xisi Road, No.20, Nantong, Jiangsu, 226001, China.
Yuejiao HuangDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, China.
Xianjuan ShenDepartment of Laboratory Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Xisi Road, No.20, Nantong, Jiangsu, 226001, China.
Ming ZhengDepartment of Laboratory Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Xisi Road, No.20, Nantong, Jiangsu, 226001, China.
Quanhua YiDepartment of Pharmacy, Affiliated Hospital of Nantong University, Pharmacy School of Nantong University, Xisi Road, No.20, Nantong, Jiangsu, 226001, China.
Zhiyuan TangDepartment of Pharmacy, Affiliated Hospital of Nantong University, Pharmacy School of Nantong University, Xisi Road, No.20, Nantong, Jiangsu, 226001, China. tzy@ntu.edu.cn.
Shaoqing JuDepartment of Laboratory Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Xisi Road, No.20, Nantong, Jiangsu, 226001, China. jsq814@hotmail.com.

Funding

Jiangsu Provincial Medical Discipline (Laboratory) ZDXK202240National Natural Science Foundation of China No. 82072363, No. 82272411National Natural Science Foundation of China No. 82473949, No. 82273955Postgraduate Research & Practice Innovation Program of Jiangsu Province KYCX25-3801Science and Technology Project of Jiangsu Province BE2023741
6 · The paper itself

Abstract

backgroundTransfer RNA-derived small RNAs (tsRNAs) have been implicated in tumor progression and immune regulation in recent years. However, the specific role of tRNA halves (tiRNAs), a subclass of tsRNAs, in modulating immunotherapy response remains unexplored. METHODS AND

resultsIn this study, 5'-tiRNA

conclusionOur findings indicate that targeting 5'-tiRNA

Indexed as

Immune Checkpoint InhibitorsImmunotherapyKetoglutarate Dehydrogenase ComplexProgrammed Cell Death 1 ReceptorRNA, TransferStomach NeoplasmsAnimalsCell Line, TumorFemaleHumansMiceImmune Checkpoint InhibitorsKetoglutarate Dehydrogenase ComplexPDCD1 protein, humanProgrammed Cell Death 1 ReceptorRNA, TransferGastric cancerGlutamine metabolismOGDHLPD-1SuccinylationtRNA-derived small RNAs

Identifiers

PMID42286727
PMCPMC13681928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.